Download PDF
Thromb Haemost 2018; 118(11): 1902-1917
DOI: 10.1055/s-0038-1673686
Cellular Haemostasis and Platelets
Georg Thieme Verlag KG Stuttgart · New York

ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw–Schulman Syndrome

Bérangère S. Joly   *
1   Institut Universitaire d'Hématologie, Université Paris Diderot, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
2   Service d'Hématologie Biologique, Université Paris Diderot, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
,
Pierre Boisseau   *
3   Service de Génétique Médicale, Hôpital Hôtel-Dieu, CHU de Nantes, Nantes, France
,
Elien Roose
4   Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Kulak Campus Kortrijk, KU Leuven, Kortrijk, Belgium
,
Alain Stepanian
1   Institut Universitaire d'Hématologie, Université Paris Diderot, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
2   Service d'Hématologie Biologique, Université Paris Diderot, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
,
Nathalie Biebuyck
5   Service de Néphrologie Pédiatrique, Hôpital Necker, Assistance Publique-Hôpitaux de Paris, Paris, France
,
Julien Hogan
6   Service de Néphrologie Pédiatrique, Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris, Paris, France
,
François Provot
7   Service de néphrologie, CHRU de Lille, Lille, France
,
Yahsou Delmas
8   Service de Néphrologie, CHU Pellegrin, Bordeaux, France
,
Céline Garrec
3   Service de Génétique Médicale, Hôpital Hôtel-Dieu, CHU de Nantes, Nantes, France
,
Karen Vanhoorelbeke
4   Laboratory for Thrombosis Research, IRF Life Sciences, KU Leuven Kulak Campus Kortrijk, KU Leuven, Kortrijk, Belgium
,
Paul Coppo
9   Département d'Hématologie Clinique, Université Pierre et Marie Curie, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France
,
Agnès Veyradier
1   Institut Universitaire d'Hématologie, Université Paris Diderot, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
2   Service d'Hématologie Biologique, Université Paris Diderot, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France
,
on behalf of the French Reference Center for Thrombotic Microangiopathies › Author Affiliations Funding This work was partly funded by a grant from the Délégation Régionale à la Recherche Clinique, Assistance Publique-Hôpitaux de Paris (PHRC AOM05012) and declared at ClinicalTrials.gov record (http://clinicaltrials.gov/show/NCT00426686, study ID number: P051064, Health Authority: France, Ministry of Health), a grant from CSL-Behring (AP-HP-2017–47–26) and a grant from Fondation d'entreprise Groupe Pasteur Mutualité. This study was also supported by the National Plan for Rare Diseases of the French Ministry of Health and the European Framework Program for Research and Innovation (HORIZON 2020 Marie Sklodowska-Curie Innovative training network PROFILE grant 675746).
Further Information

Publication History

21 January 2018

03 September 2018

Publication Date:
12 October 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Background Congenital thrombotic thrombocytopaenic purpura (TTP) or Upshaw–Schulman syndrome (USS) is a rare, life-threatening, inherited thrombotic microangiopathy (TMA). USS is mostly due to bi-allelic recessive sequence variations of the a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13) gene inducing a severe ADAMTS13 deficiency (activity < 10 IU/dL). In healthy individuals, ADAMTS13 circulates in a folded conformation where CUB domains interact with the spacer domain. The spacer–CUB interaction is abrogated when ADAMTS13 is conformationally activated.

Objective This article evaluates the influence of ADAMTS13 sequence variations on both clinical/biological phenotype and ADAMTS13 conformation in USS.

Patients and Methods All USS patients from the French registry for TMAs (1 January 2000 to 1 June 2017) were investigated for ADAMTS13 genotype, phenotype (activity, antigen and autoantibodies) and conformation. Clinical records were analysed (inaugural acute TTP and follow-up). Child-onset USS was compared with adult-onset USS.

Results Fifty-six USS patients from 51 families (34 child-onset and 22 adult-onset cases) were enrolled. Child-onset USS was characterized by a large panel of ADAMTS13 sequence variations (n = 43), spread all over ADAMTS13 gene and not correlated with either clinical features or plasmatic ADAMTS13 parameters. In contrast, adult-onset USS, consisting exclusively in pregnancy-induced TTP, included a smaller and distinct panel of ADAMTS13 sequence variations (n = 20) because of one mutation (p.Arg1060Trp) present in 82% of patients. ADAMTS13 conformation was studied in 16 USS patients (5 child-onset and 11 adult-onset USS, encompassing 16 distinct ADAMTS13 sequence variations) whose ADAMTS13 antigen levels were detectable: 14 of 16 patients (87.5%) exhibited abnormalities of ADAMTS13 conformation.

Conclusion In USS, age-onset defines two entities and ADAMTS13 sequence variations modify ADAMTS13 conformation.

Keywords

ADAMTS13 - thrombotic thrombocytopenic purpura - Upshaw–Schulman syndrome - von Willebrand factor - rare disease

* Bérangère S. Joly and Pierre Boisseau contributed equally to this work.


** Please refer to Appendix A for the complete list of French Reference Center for Thrombotic Microangiopathies.


Authors' Contributions

B.S.J. collected, analysed, interpreted data and wrote the manuscript; A.V. and P.C. designed and supervised the study and co-wrote the manuscript; B.S.J. and E.R. performed and interpreted ADAMTS13 phenotypic experiments; P.B. and C.G. performed genetic analysis and critically reviewed the manuscript; K.V. designed and supervised research, interpreted data and reviewed the manuscript for scientific content; N.B., J.H., F.P. and Y.D. included patients; A.S., N.B., J.H., F.P. and Y.D. co-analysed data and critically reviewed the manuscript. The final version of the manuscript was read and approved by all authors.


Supplementary Material

 

  • References

  • 1 Zheng XL. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 2015; 66: 211-225
    CrossrefPubMedSearch in Google Scholar
  • 2 Kremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers 2017; 3: 17020
    CrossrefPubMedSearch in Google Scholar
  • 3 Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood 2017; 130 (10) 1181-1188
    CrossrefPubMedSearch in Google Scholar
  • 4 Furlan M, Robles R, Galbusera M. , et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339 (22) 1578-1584
    CrossrefPubMedSearch in Google Scholar
  • 5 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339 (22) 1585-1594
    CrossrefPubMedSearch in Google Scholar
  • 6 Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood 2017; 129 (21) 2836-2846
    CrossrefPubMedSearch in Google Scholar
  • 7 Levy GG, Nichols WC, Lian EC. , et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413 (6855): 488-494
    CrossrefPubMedSearch in Google Scholar
  • 8 Schneppenheim R, Budde U, Oyen F. , et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003; 101 (05) 1845-1850
    CrossrefPubMedSearch in Google Scholar
  • 9 Veyradier A, Lavergne J-M, Ribba A-S. , et al. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2004; 2 (03) 424-429
    CrossrefPubMedSearch in Google Scholar
  • 10 Fujimura Y, Matsumoto M, Isonishi A. , et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011; 9 (Suppl. 01) 283-301
    CrossrefPubMedSearch in Google Scholar
  • 11 Camilleri RS, Scully M, Thomas M. , et al. A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost 2012; 10 (09) 1792-1801
    CrossrefPubMedSearch in Google Scholar
  • 12 Lotta LA, Wu HM, Mackie IJ. , et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood 2012; 120 (02) 440-448
    CrossrefPubMedSearch in Google Scholar
  • 13 Mansouri Taleghani M, von Krogh A-S, Fujimura Y. , et al. Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie 2013; 33 (02) 138-143
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Scully M, Thomas M, Underwood M. , et al; collaborators of the UK TTP Registry. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 2014; 124 (02) 211-219
    CrossrefPubMedSearch in Google Scholar
  • 15 von Krogh AS, Quist-Paulsen P, Waage A. , et al. High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence. J Thromb Haemost 2016; 14 (01) 73-82
    CrossrefPubMedSearch in Google Scholar
  • 16 Joly BS, Stepanian A, Leblanc T. , et al; French Reference Center for Thrombotic Microangiopathies. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol 2016; 3 (11) e537-e546
    CrossrefPubMedSearch in Google Scholar
  • 17 Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K. Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol 2002; 75 (01) 25-34
    CrossrefPubMedSearch in Google Scholar
  • 18 Camilleri RS, Cohen H, Mackie IJ. , et al. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost 2008; 6 (02) 331-338
    CrossrefPubMedSearch in Google Scholar
  • 19 Fujimura Y, Matsumoto M, Kokame K. , et al. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol 2009; 144 (05) 742-754
    CrossrefPubMedSearch in Google Scholar
  • 20 Moatti-Cohen M, Garrec C, Wolf M. , et al; French Reference Center for Thrombotic Microangiopathies. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119 (24) 5888-5897
    CrossrefPubMedSearch in Google Scholar
  • 21 von Krogh A-S, Kremer Hovinga JA, Tjønnfjord GE. , et al. The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications. Thromb Haemost 2014; 111 (06) 1180-1183
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Mariotte E, Azoulay E, Galicier L. , et al; French Reference Center for Thrombotic Microangiopathies. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol 2016; 3 (05) e237-e245
    CrossrefPubMedSearch in Google Scholar
  • 23 Kokame K, Matsumoto M, Soejima K. , et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002; 99 (18) 11902-11907
    CrossrefPubMedSearch in Google Scholar
  • 24 Matsumoto M, Kokame K, Soejima K. , et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2004; 103 (04) 1305-1310
    PubMedSearch in Google Scholar
  • 25 Donadelli R, Banterla F, Galbusera M. , et al; International Registry of Recurrent and Familial HUS/TTP. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 96 (04) 454-464
    Thieme ConnectPubMedSearch in Google Scholar
  • 26 Hommais A, Rayes J, Houllier A. , et al. Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). Thromb Haemost 2007; 98 (03) 593-599
    Thieme ConnectPubMedSearch in Google Scholar
  • 27 Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010; 31 (01) 11-19
    CrossrefPubMedSearch in Google Scholar
  • 28 Hing ZA, Schiller T, Wu A. , et al. Multiple in silico tools predict phenotypic manifestations in congenital thrombotic thrombocytopenic purpura. Br J Haematol 2013; 160 (06) 825-837
    CrossrefPubMedSearch in Google Scholar
  • 29 Tao Z, Peng Y, Nolasco L. , et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 2005; 106 (13) 4139-4145
    CrossrefPubMedSearch in Google Scholar
  • 30 Muia J, Zhu J, Gupta G. , et al. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A 2014; 111 (52) 18584-18589
    CrossrefPubMedSearch in Google Scholar
  • 31 South K, Luken BM, Crawley JTB. , et al. Conformational activation of ADAMTS13. Proc Natl Acad Sci U S A 2014; 111 (52) 18578-18583
    CrossrefPubMedSearch in Google Scholar
  • 32 Deforche L, Roose E, Vandenbulcke A. , et al. Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13. J Thromb Haemost 2015; 13 (11) 2063-2075
    CrossrefPubMedSearch in Google Scholar
  • 33 South K, Lane DA. ADAMTS-13 and von Willebrand factor: a dynamic duo. J Thromb Haemost 2018; 16 (01) 6-18
    CrossrefPubMedSearch in Google Scholar
  • 34 Feys HB, Anderson PJ, Vanhoorelbeke K, Majerus EM, Sadler JE. Multi-step binding of ADAMTS-13 to von Willebrand factor. J Thromb Haemost 2009; 7 (12) 2088-2095
    CrossrefPubMedSearch in Google Scholar
  • 35 Roose E, Schelpe AS, Joly BS. , et al. An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2018; 16 (02) 378-388
    CrossrefPubMedSearch in Google Scholar
  • 36 Coppo P, Schwarzinger M, Buffet M. , et al; French Reference Center for Thrombotic Microangiopathies. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 2010; 5 (04) e10208
    Search in Google Scholar
  • 37 Scully M, Cataland S, Coppo P. , et al; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017; 15 (02) 312-322
    CrossrefPubMedSearch in Google Scholar
  • 38 Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98 (06) 1765-1772
    CrossrefPubMedSearch in Google Scholar
  • 39 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129 (01) 93-100
    CrossrefPubMedSearch in Google Scholar
  • 40 Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 1999; 82 (05) 1382-1385
    Thieme ConnectPubMedSearch in Google Scholar
  • 41 Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82 (05) 1386-1389
    Thieme ConnectPubMedSearch in Google Scholar
  • 42 Hubbard AR, Heath AB, Kremer Hovinga JA. ; Subcommittee on von Willebrand Factor. Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (06) 1151-1153
    CrossrefPubMedSearch in Google Scholar
  • 43 Joly B, Stepanian A, Hajage D. , et al. Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement. Thromb Res 2014; 134 (05) 1074-1080
    CrossrefPubMedSearch in Google Scholar
  • 44 Feys HB, Roodt J, Vandeputte N. , et al. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood 2010; 116 (12) 2005-2010
    CrossrefPubMedSearch in Google Scholar
  • 45 Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115 (08) 1500-1511
    CrossrefPubMedSearch in Google Scholar
  • 46 Miyata T, Kokame K, Matsumoto M, Fujimura Y. ADAMTS13 activity and genetic mutations in Japan. Hamostaseologie 2013; 33 (02) 131-137
    Thieme ConnectPubMedSearch in Google Scholar
  • 47 Plaimauer B, Fuhrmann J, Mohr G. , et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 2006; 107 (01) 118-125
    CrossrefPubMedSearch in Google Scholar
  • 48 Schneppenheim R, Kremer Hovinga JA, Becker T. , et al. A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost 2006; 96 (01) 3-6
    Thieme ConnectPubMedSearch in Google Scholar
  • 49 Tao Z, Anthony K, Peng Y. , et al. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 2006; 4 (09) 1931-1935
    CrossrefPubMedSearch in Google Scholar
  • 50 Casina VC, Hu W, Mao J-H. , et al. High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome. Proc Natl Acad Sci U S A 2015; 112 (31) 9620-9625
    CrossrefPubMedSearch in Google Scholar
  • 51 Ishizashi H, Yagi H, Matsumoto M, Soejima K, Nakagaki T, Fujimura Y. Quantitative Western blot analysis of plasma ADAMTS13 antigen in patients with Upshaw-Schulman syndrome. Thromb Res 2007; 120 (03) 381-386
    CrossrefPubMedSearch in Google Scholar
  • 52 Tersteeg C, Schiviz A, De Meyer SF. , et al. Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 2015; 35 (11) 2336-2342
    CrossrefPubMedSearch in Google Scholar
  • 53 Joly BS, Vanhoorelbeke K, Veyradier A. Understanding therapeutic targets in thrombotic thrombocytopenic purpura. Intensive Care Med 2017; 43 (09) 1398-1400
    CrossrefPubMedSearch in Google Scholar